Menu
Search
|

Menu

Close
X

La Jolla Pharmaceutical Co LJPC.OQ (NASDAQ Stock Exchange Capital Market)

17.75 USD
+0.39 (+2.25%)
As of Oct 17
chart
Previous Close 17.36
Open 17.40
Volume 106,940
3m Avg Volume 132,150
Today’s High 18.10
Today’s Low 17.31
52 Week High 41.24
52 Week Low 15.99
Shares Outstanding (mil) 22.12
Market Capitalization (mil) 794.45
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.83 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
2
FY17
0
FY16
1
FY15
1
EPS (USD)
FY18
-4.238
FY17
-5.398
FY16
-4.537
FY15
-2.676
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.73
Price to Sales (TTM)
vs sector
6,158.55
5.82
Price to Book (MRQ)
vs sector
5.94
4.90
Price to Cash Flow (TTM)
vs sector
--
22.98
Total Debt to Equity (MRQ)
vs sector
0.00
16.96
LT Debt to Equity (MRQ)
vs sector
0.00
12.63
Return on Investment (TTM)
vs sector
-80.11
14.31
Return on Equity (TTM)
vs sector
-84.81
16.04

EXECUTIVE LEADERSHIP

Kevin Tang
Chairman of the Board, Since 2014
Salary: --
Bonus: --
George Tidmarsh
President, Chief Executive Officer, Secretary, Director, Since 2012
Salary: $571,000.00
Bonus: --
Dennis Mulroy
Chief Financial Officer, Since 2015
Salary: $359,000.00
Bonus: --
Jennifer Carver
Chief Operating Officer, Since 2017
Salary: $370,000.00
Bonus: --
James Rolke
Chief Scientific Officer, Since 2017
Salary: $350,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

4550 Towne Centre Ct
SAN DIEGO   CA   92121-1900

Phone: +1858.2074264
Site: www.ljpc.com

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH). It has initiated a Phase III trial of LJPC-501 for the treatment of CRH, called the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS) Phase III trial. LJPC-401 is its formulation of synthetic human hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is its next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections, as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.

SPONSORED STORIES